Introducing the Phase I EUPLAGIA-1 study (EudraCT 2021-003815-25), which investigated GLPG5201, a CD19 CAR T-cell therapy, in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and Richter’s transformation (RT). Patients enrolled in the study received a freshly manufactured product, with a median vein-to-vein time of 7 days. This CAR-T therapy showed encouraging efficacy with a tolerable safety profile.
vjhemonc.com/video/cc8pjzj8... - includes a 4 minute video. The speaker, Valentin Ortiz-Maldonado, MD, predicted a phase 2 study would "maybe" start next year.
Thanks, that post of yours is a virtual encyclopaedia already! You might consider yet another reference for the section on combination BTKi/ Venetoclax treatments, which also covers BTK and BCL2 resistance mechanisms healthunlocked.com/cllsuppo...
In the CAPTIVATE trial the researchers looked for known resistance mutations in BTK PLCG2 and BCL2 in patients with PD at a median follow-up of 38.9 months. They found none, leading to the possibility that the synergy of the Ibr-Ven combination extends to suppression of these resistance mutations. aacrjournals.org/clincancer...
GLPG5201 was manufactured for all pts and administered as a fresh infusion. Median vein-to-vein time was 7 days (range 7–14). ash.confex.com/ash/2023/web... which gives quite a lot of detail about the Phase 1 trial.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
CAR T Therapy
